San Diego-based Zavante Therapeutics has raised $35 million--adding it to an additional $10 million from convertible debt for the Series A round--to back a pivotal study aimed at U.S. approval of an aging antibiotic.
Sanofi Pasteur and the University of Georgia this week talked up details of a next-gen flu vaccine strategy that the pair hopes can build on the strength of current vaccines but broaden protection to avoid the problems associated with strain drift.
Texas is adding more eggs to its incubator as cancer biopharma Tesaro has inked a deal with UT's MD Anderson Cancer Center for new immuno-oncology targets.
The alarm bells are ringing at Alexza Pharmaceuticals as the small biotech announced a weak set of financials and the stark warning that without help, it will likely shut down operations by the summer.
Sanofi has poached Dr. Yong-Jun Liu as its new head of research from MedImmune as it looks to beef up its early-stage pipeline and senior R&D; leadership team.
Alder Therapeutics posted positive--and competitive--data for their Phase IIb study of a new CGRP drug for migraine, keeping it in the hectic race aimed at coming up with the first new drug approval in the crowded space.
The metalloproteins specialist Forge Therapeutics and Active Motif, which develops tools to help "turn off" certain genes, have penned a new deal in epigenetic research.
Researchers in South Korea have published details of their attempts to create a drug-delivering, glucose-monitoring microneedle patch.
The investors behind Emulate say now's the time to move their organs-on-a-chip tech to the proverbial next level, offering a $28 million B round fashioned to fuel a marketing drive and more than double the size of its staff as it gets disruptive with preclinical R&D.;
Devices to treat depression haven't had any big market breakthroughs. But key to achieving that is to show that they are a viable alternative to drug therapies--and that their impact can show a sustainable treatment benefit.